The serum at Sephora vs the syringe in your fridge. Same copper tripeptide, completely different league.
Bottom line: Start topical. It works , the clinical data on wound healing and collagen synthesis is real, and it's OTC. Escalate to injectable when you want systemic effects: full-scalp hair density, internal scar tissue from surgery, whole-body skin turnover. The sting is real, the blue solution looks alarming, and the results are a different order of magnitude from serums. Don't skip topical , it's not a consolation prize. But injectable is a different drug.
| GHK-Cu: Topical | Injectable | |
|---|---|---|
| Delivery | Creams, serums, patches , applied to skin at 0.01–2% concentration | Subcutaneous injection of reconstituted lyophilised powder. 1–2 mg/day. |
| Bioavailability | Partial. GHK-Cu at 403 Da clears the 500-Dalton rule, but it's hydrophilic , actual dermal retention is 0.6–2.8% of applied dose. Liposomal serums and ionic liquid carriers improve this significantly. | Effectively 100%. Direct absorption into bloodstream via SubQ. Reaches all tissues via circulation. |
| Mechanism | Same copper tripeptide , stimulates collagen and elastin in the dermis, inhibits MMPs, activates TIMPs, promotes angiogenesis. Effect localised to skin layers at and below application site. | Identical mechanism, systemic distribution. Modulates 4,000+ genes involved in tissue repair, antioxidant defence, and collagen synthesis across the whole body (Pickart, 2018 , PMID 29986520). |
| Reported dose | Apply 2× daily to target area. Concentration matters: anything below 0.1% is largely marketing. Look for 0.5–2%. | 1–2 mg SubQ daily. Common protocol: 1 mg/day weeks 1–2, up to 2 mg/day weeks 3–4. Reconstitute with 2 mL bacteriostatic water per 5 mg vial. |
| Cycle | Continuous use is common in skincare. No standard on/off cycle , most people use it as a permanent routine layer. | 4–6 weeks on, 4 weeks off. Some protocols run 30-day cycles: 1 mg days 1–15, 2 mg days 16–30 injected before bed. |
| Scope | Localised to application site. Excellent for face, neck, décolletage, specific scalp areas, surface scars. | Systemic. Reaches hair follicles everywhere, internal scar tissue, joints, and skin across the whole body simultaneously. |
| Onset | Skin texture reports cluster at 4–8 weeks of consistent twice-daily use. Hair effects take 8–12 weeks minimum. | Injectable users report visible skin changes from week 2–3. Hair density changes cluster at 6–8 weeks. |
| The blue colour | High-concentration topical serums can have a faint blue-green tint. Normal , that's the copper complex. Washes off. | Reconstituted solution turns distinctly blue. Not contamination, not a problem. It's the copper. Discard if the colour shifts to anything other than blue during storage. |
| Top side effect | Mild skin irritation in some formulations. Rare copper sensitivity. Generally very well tolerated even with daily use. | Injection site sting , this one genuinely hurts for 2–3 minutes. It's the copper, not the needle. Temporary redness and discolouration at the pin site. Copper taste in the mouth. Mild nausea at higher doses (>2 mg/day). |
| Evidence tier | Tier 2 , solid in vitro and clinical data for wound healing, collagen synthesis, and wrinkle reduction. MMP/TIMP studies are high quality. One of the most studied peptides in cosmetics. | Tier 2 , same peptide, same in vitro data applies. Injectable human evidence is community-driven with no controlled human trials. Dosing protocols are consensus, not RCT. |
| Common product | OTC serums: The Ordinary Buffet + Copper Peptides (1%), NIOD CAIS2 (2%). Compounded Rx topicals available at higher concentrations. | 5 mg lyophilised vials. Solution turns blue on reconstitution. 29–31G, 0.5 inch insulin syringe for SubQ. |
| Approval status | OTC cosmetic ingredient , no Rx needed. Compounded pharmaceutical-grade topical also available with prescription. | Not FDA-approved for injection. Not on the Category 1 compounded peptide list as of 2026. Research chemical status in the US. |
tierA: {"tier":2,"label":"Emerging evidence"}
tierB: {"tier":2,"label":"Emerging evidence"}
summary: GHK-Cu has the strongest evidence base of any peptide in the beauty category. Topical: in vitro data on collagen synthesis (Type I and III, up to 70–200% increase in fibroblast studies), clinical trials showing 20–30% skin firmness improvement at 12 weeks, and OTC FDA cosmetic ingredient status. Injectable: same mechanism, systemic bioavailability , but most human evidence is community-driven. The 2018 Pickart gene data (4,000+ genes modulated) applies to both routes.
trials: [{"name":"Collagen and elastin synthesis, human fibroblasts","peptide":"both","n":"in vitro","finding":"GHK-Cu at 0.01–100 nM increased Type I and III collagen production by 70–200% in aged dermal fibroblasts. Elastin synthesis also upregulated.","pmid":"3169264"},{"name":"MMP and TIMP expression, facial wrinkle parameters","peptide":"a","n":"clinical","finding":"Topical GHK-Cu reduced MMP activity, increased TIMP expression, and produced measurable wrinkle reduction in a controlled facial study.","pmid":"11045606"},{"name":"Ischemic open wound healing, rat model","peptide":"both","n":"animal","finding":"GHK-Cu accelerated wound closure, reduced metalloproteinases 2 and 9, and lowered TNF-β compared to untreated controls.","pmid":"18644225"},{"name":"Gene data: 4,000+ human genes modulated","peptide":"both","n":"genomic analysis","finding":"Pickart et al. documented modulation of over 4,000 human genes by GHK, including upregulation of DNA repair, antioxidant defence, and collagen synthesis pathways. Discovery first documented 1973.","pmid":"29986520"},{"name":"Stem cell gene expression","peptide":"both","n":"in vitro","finding":"GHK-Cu effects on stem cell activity markers and tissue remodelling gene expression documented across multiple cell types.","pmid":"24325828"},{"name":"Liposomal skin penetration , stratum corneum","peptide":"a","n":"ex vivo","finding":"GHK-Cu at 403 Daltons sits below the 500-Dalton cutoff enabling partial stratum corneum penetration. Actual dermal retention: 0.6–2.8% of applied dose. Liposomal and ionic liquid carriers significantly increase penetration.","pmid":"26236730"}]
{"applies":false,"note":"Not a stack , both sides are the same peptide via different delivery routes. You can run both simultaneously: topical for targeted surface application while cycling injectable for systemic effects. Some users do exactly this. No interaction risk. It's layered delivery of the same compound, not a combination protocol."}
It penetrates, but not deeply and not efficiently. At 403 Daltons it clears the 500-Dalton rule for stratum corneum passage. Actual dermal retention in studies is 0.6–2.8% of applied dose. Liposomal serums and ionic liquid carriers push significantly more through. Cheap thin-formula serums deliver far less than the label implies.
The copper. GHK-Cu is a copper-chelating tripeptide , when reconstituted in water, the copper complex gives the solution a distinctly blue colour. Same chemistry as the faint blue tint in high-concentration topical serums. It is completely normal. If the colour shifts from blue to something else after storage, discard it.
Nothing is wrong. The sting is the most consistently reported side effect of injectable GHK-Cu and it is caused by the copper content, not the injection technique. Lasts 2–3 minutes and fades. It is not a sign of contamination, bad reconstitution, or any error. It is the most predictable thing about this peptide.
Yes. Same peptide, no interaction. Some users apply a high-concentration topical to the face (where they are not injecting) while running a systemic injectable cycle. You're adding targeted surface concentration on top of a systemic baseline.
For diffuse, full-scalp thinning: yes. Injectable reaches every follicle via bloodstream simultaneously. Topical applied to the scalp works well for specific thinning patches. Neither route matches finasteride or minoxidil in large controlled trial evidence , but the mechanism via Wnt/beta-catenin and reduced androgen receptor sensitivity is well characterised.
Anything below 0.1% is largely marketing. Active range starts at 0.5%. Look for 0.5–2% GHK-Cu in a proper vehicle , liposomal, ionic carrier, or humectant-rich base. The Ordinary Copper Peptides is 1%. NIOD CAIS2 is 2%.
Bacteriostatic water is strongly preferred for injectable. The 0.9% benzyl alcohol inhibits microbial growth, extending shelf life of reconstituted peptide from 24–48 hours (sterile water) to 3–4 weeks refrigerated. Standard: 2 mL bac water per 5 mg vial.
Topical: skin texture clusters at 4–8 weeks of twice-daily use at active concentration. Hair effects: 8–12 weeks minimum. Injectable: visible skin changes from week 2–3; hair density changes cluster at 6–8 weeks. Collagen is a slow game either way.
Topical only , as an OTC cosmetic ingredient. The injectable form is not FDA-approved and is not on the 2026 Category 1 compounded peptide list.
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
